Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

MeSH terms

• Central Nervous System Neoplasms* / drug therapy
• Central Nervous System Neoplasms* / pathology
• Chronic Disease
• Humans
• Lymphoma* / pathology
• Neoplasm Recurrence, Local / drug therapy
• Neoplasm Recurrence, Local / pathology
• Retinal Neoplasms* / drug therapy
• Retinal Neoplasms* / pathology
• Vitreous Body / pathology